Researchers explored the question of the seasonality of SARS-CoV-2 by reviewing evidence related to viral viability, transmission, ecological patterns, and observed epidemiology of COVID-19 in the Southern Hemispheres’ summer and early fall.
A phase 3 trial evaluating an investigational antiviral antibody cocktail, REGN-COV2, for the prevention of COVID-19 has been initiated by Regeneron Pharmaceuticals.
A phase 3 trial evaluating sarilumab (Sanofi and Regeneron), an interleukin-6 antagonist, in patients with COVID-19 requiring mechanical ventilation did not meet its primary and key secondary end points.
Meteorologists and health experts are warning that a huge blanket of Sahara Desert dust will engulf parts of the United States this week.
Estimates of the severity of coronavirus disease 2019 (COVID-19) using model-based analysis showed a mean time from symptom onset to death of roughly 18 days.
The Food and Drug Administration (FDA) has approved Symdeko (tezacaftor/ivacaftor and ivacaftor; Vertex Pharmaceuticals) for the treatment of patients aged ≥6 years with cystic fibrosis (CF) who are homozygous for the F508del mutation or who have at least 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor. Previously,…
Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional.
High-dose influenza vaccination can reduce risk of respiratory-related hospitalization among nursing home residents.
